Izokibep Demonstrates Clinically Relevant Efficacy Benefits on Enthesitis, Dactylitis and Nail Outcomes in Active PsA Patients: A 16-week Randomized, Placebo-controlled Trial

izokibep (ABY-035) - Affibody, ACELYRIN

https://www.eventscribe.net/2022/ACRConvergence/fsPopup.asp?Mode=presInfo&PresentationID=1130483

Kurt de Vlam1; Peter Taylor2; Philip J Mease3; Paul Peloso4; Dieter Wetzel5; Nicolai Brun5; Brian Wiens6; Jan Brandt-Juergens7; Edit Drescher8; Eva Dokoupilova9; Anna Rowinska-Osuch10; Nadia Abdel- Kader Martin11; Frank Behrens12

Sep 17, 2022